Generation Bio Co.
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
GBIO | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 301 BINNEY STREET, 2142 CAMBRIDGE
- Website:
- https://generationbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Generation Bio Co. is a biotechnology company developing a new class of genetic medicines for T cell-driven autoimmune diseases. The company's platform utilizes cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This approach enables potent gene silencing to modulate or reduce autoreactive T cells that cause organ and tissue damage, while sparing the broader immune system. Generation Bio aims to create more potent, precise, and better-tolerated redosable therapeutics, unlocking the full potential of siRNA to treat autoimmune conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Generation Bio Co. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Generation Bio Co.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Generation Bio Co. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
